2016/10 – IR call – Dupilumab | PPT
Phase 3 Study of Dupilumab Monotherapy in Adolescent Patients Aged 12-17 Years With Moderate-to-Severe AD Clinical Development
Dermatite atopica severa. La CE approva dupilumab per i bambini di età compresa tra 6 mesi e 5 anni - SOCIALFARMA
RIASSUNTO DELLE CARATTERISTICHE DEL PRODOTTO
SOLO 1 and SOLO 2 Trials Could Strengthen Dupixent's Label
Sanofi and Regeneron Announce Approval of Dupixent » FINCHANNEL
Dupilumab Efficacy (continued) | Download Scientific Diagram
ADvocate and SOLO-CONTINUE trial designs. The arms used in this study... | Download Scientific Diagram
Efficacy of dupilumab 300 mg q2w monotherapy for atopic dermatitis... | Download Scientific Diagram
Resolution of conjunctivitis events during the treatment period:... | Download Scientific Diagram
Dupixent: Package Insert - Drugs.com
Clinical Evidence - Clinical Review Report: Dupilumab (Dupixent) - NCBI Bookshelf
Dermatite atopica: trattamenti sistemici emergenti e novità terapeutiche | Bollettino SIFO - Bollettino della Società Italiana di Farmacia Ospedaliera e dei Servizi Farmaceutici delle Aziende Sanitarie
2022.1.2.dupilumab_atopic_dermatitis - Our Dermatology Online
UNITED STATES SECURITIES AND EXCHANGE COMMISSION FORM 8-K REGENERON PHARMACEUTICALS, INC.
Management of dupilumab-associated ocular surface diseases in atopic dermatitis patients
Dupixent, INN-dupilumab
Clinical Evidence - Clinical Review Report: Dupilumab (Dupixent) - NCBI Bookshelf
Positive opinion for dupilumab in moderate to severe atopic dermatitis - Hospital Pharmacy EuropeHospital Pharmacy Europe
JCM | Free Full-Text | Predictive Factors of Early Response to Dupilumab in Patients with Moderate-to-Severe Atopic Dermatitis
Dupixent, INN-dupilumab
Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.,JAMA Dermatology - X-MOL
A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up | Dermatology and Therapy
A Review of Phase 3 Trials of Dupilumab for the Treatment of Atopic Dermatitis in Adults, Adolescents, and Children Aged 6 and Up | Dermatology and Therapy
Dupilumab Improves Asthma and Sinonasal Outcomes in Adults with Moderate to Severe Atopic Dermatitis
